EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine

David García-Azorín iD, Cristina Martínez-Badillo, Javier Camiña Muñiz, Ana Beatriz Gago-Veiga, Noemi Morollón Sánchez iD, Vicente González-Quintanilla, Jesús Porta-Etessam iD, Alvaro Sierra-Mencía, Nuria González-García, Yésica González-Osorio, Marcos Polanco-Fernandez iD, Andrea Recio-García und 2 weitere

Cephalalgia · 2024-04 · 44 (4)

DOI: 10.1177/03331024241248833 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 25.04.2024. Verfasst von David García-Azorín und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Biphenyl Compounds, Benzimidazoles, Tetrazoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Effectiveness of candesartan in migraine prevention is supported by two randomized controlled trials. We aimed to assess the effectiveness, tolerability, and response predictors of candesartan in the preventive treatment of migraine.

Methods

Observational, multicenter, prospective cohort study. The 50%, 75% and 30% responder rates, between weeks 8–12 and 20–24, were compared with the baseline. Treatment emergent adverse effects were systematically evaluated. Response predictors were estimated by multivariate regression models.

Results

Eighty-six patients were included, 79.1% females, aged 39.5 (inter-quartile range [IQR] 26.3–50.3), with chronic migraine (43.0%), medication overuse headache (55.8%) and a median of two (inter-quartile range: 0.75–3) prior preventive treatments. At baseline patients had 14 (10–24) headache and 8 (5–11) migraine days per month. The 30%, 50% and 75% responder rates were 40%, 34.9% and 15.1% between weeks 8–12, and 48.8%, 36%, and 18.6% between weeks 20–24. Adverse effects were reported by 30 (34.9%) and 13 (15.1%) patients between weeks 0–12 and 12–24, leading to discontinuation in 15 (17.4%) patients. Chronic migraine, depression, headache days per month, medication overuse headache, and daily headache at baseline predicted the response between weeks 20–24.

Conclusion

Candesartan effectiveness and tolerability in migraine prevention was in line with the clinical trials’ efficacy.

Trial registration

The study protocol is registered in ClinicalTrials.gov (NCT04138316).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersBiphenyl CompoundsBenzimidazolesTetrazolesHumansFemaleMaleAdultMiddle AgedTreatment OutcomeProspective StudiesAngiotensin II Type 1 Receptor BlockersSpainCohort Studies

Stichwörter der Autor:innen

Headache disordersangiotensin II type 1 receptor blockershypertensionmigraineprimary

Substanzen

Biphenyl CompoundsBenzimidazolescandesartanTetrazolesAngiotensin II Type 1 Receptor Blockers

Autor:innen und Institutionen

  • Department of Medicine, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain.
  • Headache Unit, Department of Neurology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Valladolid East Primary Care, Regional Health Administration, Gerencia Regional de Salud, Junta de Castilla y Leon, Valladolid, Spain.
  • Headache Unit, Department of Neurology, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
  • Department of Neurology, Clinica Rotger Quironsalud, Palma de Mallorca, Spain.
  • Headache Unit, Department of Neurology, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain.

ORCID-Profile: David García-Azorín, Noemi Morollón Sánchez, Jesús Porta-Etessam, Marcos Polanco-Fernandez, Angel Luis Guerrero-Peral

Zitieren

APA

García-Azorín, D., Martínez-Badillo, C., Camiña Muñiz, J., Gago-Veiga, A. B., Morollón Sánchez, N., González-Quintanilla, V., Porta-Etessam, J., Sierra-Mencía, A., González-García, N., González-Osorio, Y., Polanco-Fernandez, M., Recio-García, A., Belvis Nieto, R., & Guerrero-Peral, A. L. (2024). CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine. Cephalalgia, 44(4). https://doi.org/10.1177/03331024241248833

Vancouver

García-Azorín D, Martínez-Badillo C, Camiña Muñiz J, Gago-Veiga AB, Morollón Sánchez N, González-Quintanilla V, et al. CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine. Cephalalgia. 2024;44(4). doi:10.1177/03331024241248833

BibTeX
@article{GarcaAzorn2024,
  author = {García-Azorín, David and Martínez-Badillo, Cristina and Camiña Muñiz, Javier and Gago-Veiga, Ana Beatriz and Morollón Sánchez, Noemi and González-Quintanilla, Vicente and Porta-Etessam, Jesús and Sierra-Mencía, Alvaro and González-García, Nuria and González-Osorio, Yésica and Polanco-Fernandez, Marcos and Recio-García, Andrea and Belvis Nieto, Robert and Guerrero-Peral, Angel Luis},
  title = {CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine},
  journal = {Cephalalgia},
  year = {2024},
  volume = {44},
  number = {4},
  doi = {10.1177/03331024241248833}
}
Kostenlos starten →